Table 1.
Model inputs
| Baseline characteristics | Simulated cohort |
|---|---|
| Male, % [12] | 73.8 |
| Age [years], % [12] | |
| 18–34 | 11.0 |
| 35–54 | 65.5 |
| 55–75 | 23.5 |
| CVD, % [39] | 1.1 |
| COPD, % [29] | 2.2 |
| FTND score, mean (SD) [12] | 3.9 (2.3) |
| Years smoked, mean (SD) [12] | 23.4 (7.2) |
| Number of prior quit attempts, mean (SD) [12] | 1.5 (2.3) |
| Intervention | Quit attempt cost (¥; 2014 values) [5] |
|---|---|
| Varenicline | 65,510 |
| NRT | 43,620 |
| BMT | 9620 |
| Unassisted | 0 |
| Smoking-related diseases | Annual costs (¥; 2014 values) [44, 45] | Utilities |
|---|---|---|
| MI | 1,036,000 | 0.88 [38] |
| Stroke | 1,780,000 | 0.56 [47] |
| COPD | 678,000 | 0.79 [27] |
| Lung cancer | 3,381,000 | 0.87 [38] |
| Stomach cancer | 1,610,000 | 0.87 [38] |
| Hepatic cancer | 2,499,000 | 0.87 [38] |
¥ Japanese yen, BMT behavioural modification therapy, COPD chronic obstructive pulmonary disease, CVD cardiovascular disease, FTND Fagerström test for nicotine dependence, MI myocardial infarction, NRT nicotine replacement therapy, SD standard deviation